A Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Genentech
ClinicalTrials.gov Identifier:
NCT01546519
First received: March 2, 2012
Last updated: September 2, 2014
Last verified: September 2014

March 2, 2012
September 2, 2014
March 2012
April 2014   (final data collection date for primary outcome measure)
  • Maximum observed plasma concentration (Cmax) [ Time Frame: up to 8 days ] [ Designated as safety issue: No ]
  • Steady-state area under the plasma concentration-time curve (AUC0-24hr) [ Time Frame: up to 8 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01546519 on ClinicalTrials.gov Archive Site
  • Time to maximum plasma concentration (Tmax) [ Time Frame: up to 8 days ] [ Designated as safety issue: No ]
  • Minimum plasma concentration (Cmin) [ Time Frame: up to 8 days ] [ Designated as safety issue: No ]
  • Apparent clearance (CL/F) [ Time Frame: up to 8 days ] [ Designated as safety issue: No ]
  • Amount of vismodegib in 24-hour total urine, and renal clearance (CLR) [ Time Frame: up to 8 days ] [ Designated as safety issue: No ]
  • Apparent non-renal clearance (CLNR/F) [ Time Frame: up to 8 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
A Phase Ib Open-Label Pharmacokinetics and Safety Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function

This is a Phase Ib, open-label, multiple-center, multiple-dose study designed to evaluate the pharmacokinetics and safety of vismodegib in patients with advanc ed solid malignancies (including hepatocellular carcinoma and lymphoma) that ar e refractory to standard therapy or for whom no standard therapy exists.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Solid Cancers
Drug: Vismodegib
oral repeating dose
  • Experimental: 1
    Control cohort with normal renal and normal hepatic function
    Intervention: Drug: Vismodegib
  • Experimental: 2
    Severe renal impairment and normal hepatic function
    Intervention: Drug: Vismodegib
  • Experimental: 3
    Mild hepatic impairment and normal renal function
    Intervention: Drug: Vismodegib
  • Experimental: 4
    Moderate hepatic impairment and normal renal function
    Intervention: Drug: Vismodegib
  • Experimental: 5
    Severe hepatic impairment and normal renal function
    Intervention: Drug: Vismodegib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
31
April 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed advanced solid malignancy (including hepatocellular carcinoma and lymphoma) that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
  • Eastern Cooperative Oncology Group (ECOG) performance status </= 2 (Karnofsky >/=60%)
  • Acceptable bone marrow functions
  • Normal or varying degrees of renal or hepatic impairment according to NCI Organ Dysfunction Working Group criteria.
  • Organ function should be stable for at least 2 weeks before Day 1. In addition, there should be no evidence of acute exacerbation of hepatic/renal disease.
  • Patients with gliomas or known brain metastases who require corticosteroids or anticonvulsants must be on a stable dose of corticosteroids and seizure free for 1 month prior to enrollment. Patients with known brain metastases must be at least 4 weeks out from any radiation before starting the protocol (Day 1).
  • Documented negative serum pregnancy test for women of childbearing potential
  • For women of childbearing potential, agreement to the use of two acceptable methods of contraception during the study and for 7 months after discontinuation of vismodegib
  • For men with female partners of childbearing potential, agreement to use a latex, non-latex, or any other male condom and to advise their female partners to use an additional acceptable method of birth control during the study and for 2 months after discontinuation of study drug
  • Agreement not to donate blood/blood products during the study and for 7 months after discontinuing study drug
  • For men with normal renal and hepatic function, agreement to provide semen during the vismodegib treatment period for study assessment (optional), but otherwise NOT to donate semen during the vismodegib treatment period and for 2 months after discontinuation of study drug

Exclusion Criteria:

  • Pregnancy or lactation
  • Chemotherapy, biologic therapy, immunotherapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
  • Investigational agents within 28 days prior to study entry (Day 1)
  • Use of Pgp inhibitors within 7 days of Day 1
  • Use of gastric pH altering drugs except antacids within 7 days of Day 1
  • Major surgery within 14 days prior to treatment (Day 1). Patients with recent major surgery must have recovered from that surgery. Patients who are expected to have any major surgery during the study treatment period should not be enrolled.
  • Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of vismodegib or that might affect interpretation of the results from this study or renders the patient at high risk from treatment complications.
  • Severely impaired renal function (Cohort 2 only) should not have active hemolysis, and should not be on hemodialysis or peritoneal dialysis during the screening and study treatment period (Days 1-9).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01546519
GP27839
Not Provided
Genentech
Genentech
Not Provided
Study Director: Clinical Trials Genentech
Genentech
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP